WuXi Bio, InnoCare tap equity investors for HK$16bn

Jonathan Breen

February 03, 2021 08:00 am

Chinese biopharmaceutical duo WuXi Biologics (Cayman) and InnoCare Pharma raised a combined HK$16.2bn ($2.1bn) on Tuesday from selling new stock.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP Morgan Equity China Hong Kong SAR Asia Follow-ons and Rights Issues Asia Greater China Morgan Stanley Northeast Asia Asia Pacific Follow-ons and Rights issues Emerging Markets Goldman Sachs

JB

Jonathan Breen

Equities editor GlobalCapital Asia